A new treatment offers hope for advanced-stage, metastatic castration-resistant prostate cancer (mCRPC). Therapy options are limited for men with advanced prostate cancer.
In the featured article of The Journal of Nuclear Medicine's, German researchers report on their recent clinical experience, which establishes a dosing regimen for actinium-225 (225Ac)-labeled targeted alpha therapy of patients with prostate-specific membrane antigen (PSMA)-positive tumors.
Brachytherapy for Prostate Cancer
Learn about two different types of brachytherapy used for treating prostate cancer. Get information on the latest advances in the field.
Advertisement
‘A new treatment protocol that presents a promising trade-off between toxicity and anti-tumor activity of PSMA-directed targeted alpha therapy developed.’
Tweet it Now
The protocol balances treatment response with toxicity concerns to provide the most effective therapy with the least side effects.
"The idea of targeted alpha therapy is not completely novel," explains Clemens Kratochwil, MD, University Hospital Heidelberg in Germany. "However, in contrast to hundreds of preclinical research reports, the clinical experience is still very limited. Our current results present a milestone about clinical translation because we could demonstrate how preclinical knowledge can be applied to human beings."
![Decipher Test for Prostate Cancer]( "Decipher Test for Prostate Cancer")
Decipher test a genomic test for prostate cancer that determines the aggressiveness of the cancer and helps in planning the treatment course for the cancer.
Salvage therapy results show treatment with 100kBq/kg 225Ac-PSMA-617 is tolerated by patients and demonstrates a promising anti-tumor response. Also, it was determined that repeated treatments at intervals of eight weeks might lead to continuing tumor control.
"We developed a treatment protocol that presents a promising trade-off between toxicity and anti-tumor activity of PSMA-directed targeted alpha therapy," says Kratochwil.
"However, our current results present only a starting-dose that, on the one hand, has still to be optimized and, on the other hand, needs further studies to evaluate its efficacy. Ultimately, there could be a new treatment modality to improve symptomatic patients and prolong survival."
Looking ahead, Kratochwil states, "If PSMA-targeted alpha therapy keeps its promise, it may earn a significant place in therapeutic nuclear medicine. However, it is the nature of all molecular targeting therapies that they can only be useful if the target is sufficiently expressed in the tumors.
Thus, molecular imaging using PSMA-PET/CT also has an important role as a stratification criterion, and the 'theranostic' concept [combining diagnostic imaging of a biomarker with precise therapy] may be an additional motivation to establish PSMA-PET/CT as a routinely available imaging modality."
Source: Eurekalert
Decipher Test for Prostate Cancer
Decipher test a genomic test for prostate cancer that determines the aggressiveness of the cancer and helps in planning the treatment course for the cancer.
Advertisement
Salvage therapy results show treatment with 100kBq/kg 225Ac-PSMA-617 is tolerated by patients and demonstrates a promising anti-tumor response. Also, it was determined that repeated treatments at intervals of eight weeks might lead to continuing tumor control.
"We developed a treatment protocol that presents a promising trade-off between toxicity and anti-tumor activity of PSMA-directed targeted alpha therapy," says Kratochwil.
"However, our current results present only a starting-dose that, on the one hand, has still to be optimized and, on the other hand, needs further studies to evaluate its efficacy. Ultimately, there could be a new treatment modality to improve symptomatic patients and prolong survival."
Looking ahead, Kratochwil states, "If PSMA-targeted alpha therapy keeps its promise, it may earn a significant place in therapeutic nuclear medicine. However, it is the nature of all molecular targeting therapies that they can only be useful if the target is sufficiently expressed in the tumors.
Thus, molecular imaging using PSMA-PET/CT also has an important role as a stratification criterion, and the 'theranostic' concept [combining diagnostic imaging of a biomarker with precise therapy] may be an additional motivation to establish PSMA-PET/CT as a routinely available imaging modality."
Source: Eurekalert
External Beam Radiation Therapy for Prostate Cancer
In depth information about various types of external beam radiotherapy for treatment of prostate cancer. Radiotherapy is an alternative to surgical treatment such as radical prostatectomy.
Advertisement
 Prostate CancerThis cancer affects men over the age of 50 years and screening with rectal examination and PSA can help both in early detection and effective treatment | Advertisement
|
Advertisement
Recommended Readings
![Prostate Specific Antigen [PSA]](https://www.medindia.net/images/patientinfo/120x100/prostate-specific-antigen.jpg "Prostate Specific Antigen [PSA]")
Latest Cancer News
The effects and mechanisms of microRNA-451a (miR-451a), which hinders the progression of gemcitabine-resistant biliary tract cancers, are under study.
The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.
A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.
Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.
Examining breast cancer occurrence and stages reveals disparities in urban versus rural rates, influenced by environmental conditions and the stage of the disease.